Prevalence of PCV, RAP and CNV in eyes with presumed neovascular AMD requiring ≥8 intravitreal ranibizumab injections during PRN treatment
| Prevalence, n (%) | Overall (n=202) | Group 1* (n=149) | Group 2† (n=53) |
|---|---|---|---|
| PCV | 34 (16.8) | 32 (21.5) | 2 (3.8)‡ |
| RAP | 23 (11.4) | 16 (10.7) | 7 (13.2) |
| AMD-type CNV | 145 (71.8) | 101 (67.8) | 44 (83.0) |
| CNV feeder vessels | 60 (29.7) | 46 (30.9) | 14 (26.4) |
| Geographic atrophy with small occult CNV | 9 (4.5) | 6 (4.0) | 3 (5.7) |
*<12 months between injections 1 and 6.
†≥12 months between injections 1 and 6.
‡p=0.003 versus group 1.
AMD, age-related macular degeneration; CNV, choroidal neovascularisation; PCV, polypoidal choroidal vasculopathy; PRN, pro re nata (as needed); RAP, retinal angiomatous proliferation.